Also Read: Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know. Results showed VK0214 to be safe and well-tolerated following ...

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to discuss the use of medication to treat mental health and the ...

Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing it closer to joining the highly competitive GLP-1 drug market, STAT tells us.

Hsieh also said Viking's pill showed a "highly benign tolerability profile," referring to how well patients tolerated the drug. Six of nine ... protect the patient's health. Abortions are ...

Viking previously reported positive results from ... Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various ...

Health care companies fell as traders fled risky niches of the sector. Shares of Viking Therapeutics slid ... called "rapid" enrollment for the drug developer's widely anticipated obesity drug ...

Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected ... as they attempt to show the broad health benefits of the GLP-1 therapies that have ...

Maggie O’Neill is a health writer and ... would work similarly to other medications in this category, such as Zepbound and Mounjaro. Some companies, including Viking Therapeutics and AstraZeneca ...

including Viking’s sped-up plans in obesity, the departure of a long time official at the Food and Drug Administration, and Kamala Harris’ views on health policies.

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics ... by the U.S. Food and Drug Administration and ...